

# CITATION REPORT

List of articles citing

Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers

DOI: 10.1136/ard.58.4.253

Annals of the Rheumatic Diseases, 1999, 58, 253-6.

**Source:** <https://exaly.com/paper-pdf/30868787/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
90	Sjögren's syndrome: current therapies remain inadequate for a common disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2000</b> , 9, 2007-16	5.9	27
89	Farmacos con actividad de fondo en patologí inflamatoria articular (I). <i>Medicine</i> , <b>2000</b> , 8, 1457-1463	0.1	
88	Hydroxychloroquine enhances the endocrine secretion of adenovirus-directed growth hormone from rat submandibular glands in vivo. <i>Human Gene Therapy</i> , <b>2001</b> , 12, 1333-41	4.8	35
87	Collaborative research into outcome measures in Sjögren's syndrome. Update on disease assessment. <i>Scandinavian Journal of Rheumatology</i> , <b>2002</b> , 116, 23-7	1.9	18
86	Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 49, 394-8		50
85	Salivary gland scintigraphy in Sjögren's syndrome and patients with sicca symptoms but without Sjögren's syndrome: the psychological profiles and predictors for salivary gland dysfunction. <i>Annals of the Rheumatic Diseases</i> , <b>2003</b> , 62, 964-8	2.4	16
84	Rheumatologic Diseases. <b>2003</b> , 573-619		0
83	Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. <i>Rheumatology</i> , <b>2004</b> , 43, 758-64	3.9	137
82	Primary Sjögren's syndrome: new clinical and therapeutic concepts. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 347-54	2.4	183
81	An update of the etiology and management of xerostomia. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , <b>2004</b> , 97, 28-46		227
80	Differential responses of serum and salivary interleukin-6 to acute strenuous exercise. <i>European Journal of Applied Physiology</i> , <b>2005</b> , 93, 679-86	3.4	44
79	Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 1050-5	2.4	59
78	Lamivudine is not effective in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 1326-30	2.4	8
77	[Synthetic antimalarials]. <i>Annales De Dermatologie Et De Venereologie</i> , <b>2005</b> , 132, 665-74	0.3	5
76	[Sjögren syndrome. New therapeutic approaches]. <i>Medicina Clínica</i> , <b>2005</b> , 124, 111-5	1	3
75	[Sjögren's syndrome. Current aspects from a rheumatological point of view]. <i>Zeitschrift Fur Rheumatologie</i> , <b>2006</b> , 65, 505-17; quiz 518-9	1.9	10
74	Management of patients presenting with Sjogren's syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2006</b> , 20, 791-807	5.3	30

73	New approaches in Sjögren's syndrome therapy. <i>Expert Review of Clinical Immunology</i> , <b>2007</b> , 3, 195-204	5.1	6
72	Preventive effect of <i>Ophiopogon japonicus</i> polysaccharides on an autoallergic mouse model for Sjögren's syndrome by regulating the Th1/Th2 cytokine imbalance. <i>Journal of Ethnopharmacology</i> , <b>2007</b> , 114, 246-53	5	24
71	Syndrome de Gougerot-Sjögren: critères de classification, lymphomes, traitements. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2007</b> , 74, 737-744	0.1	0
70	Primary Sjögren's syndrome: current and prospective therapies. <i>Seminars in Arthritis and Rheumatism</i> , <b>2008</b> , 37, 273-92	5.3	58
69	Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome. <i>Rheumatic Disease Clinics of North America</i> , <b>2008</b> , 34, 1011-23, x	2.4	8
68	Current and prospective treatment options for Sjögren's syndrome. <i>Expert Review of Clinical Immunology</i> , <b>2008</b> , 4, 469-79	5.1	4
67	Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial. <i>Modern Rheumatology</i> , <b>2009</b> , 19, 114-124	3.3	21
66	Sjögren's Syndrome. <b>2009</b> , 107-130		5
65	Casi clinici di due bambini con sindrome di Sjögren primaria. <i>Archivio Di Ortopedia E Reumatologia</i> , <b>2010</b> , 121, 45-46		
64	Rheumatoid arthritis and salivary biomarkers of periodontal disease. <i>Journal of Clinical Periodontology</i> , <b>2010</b> , 37, 1068-74	7.7	70
63	Primary Sjögren's syndrome: too dry and too tired. <i>Rheumatology</i> , <b>2010</b> , 49, 844-53	3.9	88
62	Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , <b>2010</b> , 110, 62-7		20
61	Implications of long-term medication of oral steroids and antimalarial drugs in primary Sjögren's syndrome. <i>International Immunopharmacology</i> , <b>2011</b> , 11, 2125-9	5.8	5
60	Antimalarials and SLE. <b>2011</b> , 1061-1081		0
59	Activation of the alternative NFB pathway improves disease symptoms in a model of Sjögren's syndrome. <i>PLoS ONE</i> , <b>2011</b> , 6, e28727	3.7	24
58	Use of hydroxychloroquine in Japan. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 1296	4.1	7
57	Recurrent parotitis as a presentation of primary pediatric Sjögren syndrome. <i>Pediatrics</i> , <b>2012</b> , 129, e179-82	4.4	32
56	Topical and systemic medications for the treatment of primary Sjögren's syndrome. <i>Nature Reviews Rheumatology</i> , <b>2012</b> , 8, 399-411	8.1	123

55	Cytotoxics or biologicals in the treatment of Sjögren's syndrome?. <i>International Journal of Clinical Rheumatology</i> , <b>2012</b> , 7, 63-72	1.5	
54	Biologic treatments in Sjögren's syndrome. <i>Presse Medicale</i> , <b>2012</b> , 41, e495-509	2.2	12
53	Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese. <i>Revista Brasileira De Reumatologia</i> , <b>2013</b> , 53, 483-493		0
52	Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese. <i>Revista Brasileira De Reumatologia</i> , <b>2013</b> , 53, 483-93		14
51	Oral dryness in Sjögren's syndrome patients. Not just a question of water. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 567-74	13.6	55
50	Effects of total glucosides of paeony for delaying onset of Sjogren's syndrome: an animal study. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , <b>2013</b> , 41, 610-5	3.6	24
49	Effect of hydroxychloroquine on the lipid profile of patients with Sjögren syndrome. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 902-8	4.1	16
48	Hydroxychloroquine: a multifaceted treatment in lupus. <i>Presse Medicale</i> , <b>2014</b> , 43, e167-80	2.2	101
47	Recommendations for the treatment of Sjögren's syndrome. <i>Revista Brasileira De Reumatologia</i> , <b>2015</b> , 55, 446-457		0
46	Recommendations for the treatment of Sjögren's syndrome. <i>Revista Brasileira De Reumatologia</i> , <b>2015</b> , 55, 446-57		16
45	Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 2105-17	2.5	22
44	Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study. <i>Journal of Korean Medical Science</i> , <b>2016</b> , 31, 1127-35	4.7	35
43	New Treatment Guidelines for Sjögren's Disease. <i>Rheumatic Disease Clinics of North America</i> , <b>2016</b> , 42, 531-51	2.4	82
42	Serum, Synovial, and Salivary Biomarkers for Orofacial Pain Conditions. <b>2017</b> , 119-131		
41	Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 891-897	2.4	55
40	Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 2455-2460	3.9	17
39	The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. <i>Rheumatology</i> , <b>2017</b> , 56, e24-e48	3.9	9
38	Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis. <i>BMC Musculoskeletal Disorders</i> , <b>2017</b> , 18, 186	2.8	44

37	Clinical significance of serum and urinary interleukin-6 in systemic lupus erythematosus patients. <i>Egyptian Rheumatologist</i> , <b>2017</b> , 39, 1-6	1	7
36	Hydroxychloroquine: Looking into the Future. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , <b>2017</b> , 24, 369-375	0.2	4
35	Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. <i>Journal of Inflammation</i> , <b>2017</b> , 14, 26	6.7	27
34	Sjögren's Syndrome. <b>2017</b> , 281-300		
33	Optimizing conventional DMARD therapy for Sjögren's syndrome. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 480-493	3.6	15
32	Interferon activation in primary Sjögren's syndrome: recent insights and future perspective as novel treatment target. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 817-829	5.1	17
31	Sjogren's Syndrome. <b>2019</b> , 559-567		
30	Innate immunity and interferons in the pathogenesis of Sjögren's syndrome. <i>Rheumatology</i> , <b>2019</b> ,	3.9	26
29	How to treat Sjögren's syndrome. <i>Rheumatology</i> , <b>2019</b> ,	3.9	5
28	Clinimetrics in Sjögren's syndrome. <i>Revista Colombiana De Reumatología (English Edition)</i> , <b>2019</b> , 26, 260-267	3.1	0
27	Viral antigens elicit augmented immune responses in primary Sjögren's syndrome. <i>Rheumatology</i> , <b>2020</b> , 59, 1651-1661	3.9	10
26	Pharmacological Management of Sjögren's Syndrome. <b>2021</b> , 197-215		0
25	An unusual cause of immune complex-mediated membranoproliferative glomerulonephritis in a child: Answers. <i>Pediatric Nephrology</i> , <b>2021</b> , 36, 2307-2310	3.2	
24	Current and future therapies for primary Sjögren syndrome. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 475-486	8.1	10
23	Efficacy of hydroxychloroquine for treating annular erythema associated with Sjögren's syndrome. <i>Journal of Dermatology</i> , <b>2021</b> , 48, 1526-1532	1.6	0
22	The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 693796	5.6	0
21	Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial. <i>Modern Rheumatology</i> , <b>2009</b> , 19, 114-24	3.3	10
20	IL-6: Relevance for immunopathology of SARS-CoV-2. <i>Cytokine and Growth Factor Reviews</i> , <b>2020</b> , 53, 13-24	4.9	141

19	A Case of Kidney Involvement in Primary Sjögren's Syndrome. <i>American Journal of Case Reports</i> , <b>2017</b> , 18, 622-626	1.3	3
18	Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren's syndrome. <i>F1000Research</i> , <b>2019</b> , 8,	3.6	9
17	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e12476	12	29
16	COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?. <i>Aging</i> , <b>2020</b> , 12, 6511-6517	5.6	123
15	Pharmakotherapie. <b>2007</b> , 129-174		
14	Non-neoplastic salivary gland diseases. <b>2008</b> , 1898-1920		
13	Sjögren's Syndrome in Israel: A Scientific Point of View. <b>2011</b> , 437-439		
12	Current Treatment of Extraglandular Manifestations with Disease-Modifying and Immunosuppressive Agents. <b>2011</b> , 337-344		
11	Classic Immunosuppressive and Immunomodulatory Drugs. <b>2011</b> , 565-569		
10	Pharmakotherapie. <b>2014</b> , 121-168		
9	Clinimetría en el síndrome de Sjögren. <i>Revista Colombiana De Reumatología</i> , <b>2019</b> , 26, 262-269	0.2	1
8	RHEUMATISCHE ERKRANKUNGEN. <b>2020</b> , I-1-I8-7		
7	Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. <i>Inflammopharmacology</i> , <b>2021</b> , 29, 1795-1805	5.1	
6	An Update on Sjögren's Syndrome for Oral Medicine Specialists. <i>Journal of Oral Medicine and Pain</i> , <b>2021</b> , 46, 99-108	0.2	
5	Renal Involvement in Sjogren S Syndrome. <i>Medicina Interna (Bucharest, Romania: 1991)</i> , <b>2022</b> , 19, 115-120.1		
4	Lokal og systemisk behandling av munntørhet. <b>2013</b> , 123,		0
3	Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome. <b>2023</b> , 24, 1331		0
2	Salivary gland LAMP3 mRNA expression is a possible predictive marker in the response to hydroxychloroquine in Sjögren's disease. <b>2023</b> , 18, e0282227		0

1 Sjögren's Disease. **2023**, 133-165

o